<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557295</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P13 4.2</org_study_id>
    <nct_id>NCT02557295</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA</brief_title>
  <official_title>An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in&#xD;
      Patients with Rheumatoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the long-term safety of Remsima™ in&#xD;
      Rheumatoid Arthritis (RA) patients by evaluation of events of special interest (ESI) up to 5&#xD;
      years and to exploratory compare patients receiving Remsima™ with patients receiving&#xD;
      non-biologic treatments or other anti-TNF drugs.&#xD;
&#xD;
      In order to assess the primary study outcomes, the following ESI will be evaluated:&#xD;
&#xD;
        -  Hepatitis B virus reactivation&#xD;
&#xD;
        -  Congestive heart failure&#xD;
&#xD;
        -  Opportunistic infection (excluding tuberculosis)&#xD;
&#xD;
        -  Serious infections including sepsis (excluding opportunistic infections and&#xD;
           tuberculosis)&#xD;
&#xD;
        -  Tuberculosis (TB)&#xD;
&#xD;
        -  Serum sickness (delayed hypersensitivity reactions)&#xD;
&#xD;
        -  Haematologic reactions&#xD;
&#xD;
        -  Systemic lupus erythematosus/lupus like syndrome&#xD;
&#xD;
        -  Demyelinating disorders&#xD;
&#xD;
        -  Lymphoma (not HSTCL)&#xD;
&#xD;
        -  Hepatobiliary events&#xD;
&#xD;
        -  Hepatosplenic T cell lymphoma (HSTCL)&#xD;
&#xD;
        -  Serious infusion reactions during a re-induction regimen following disease flare&#xD;
&#xD;
        -  Sarcoidosis/sarcoid-like reactions&#xD;
&#xD;
        -  Leukaemia&#xD;
&#xD;
        -  Malignancy (excluding lymphoma)&#xD;
&#xD;
        -  Skin cancer&#xD;
&#xD;
        -  Pregnancy exposure†&#xD;
&#xD;
        -  Infusion reaction associated with shortened infusion duration&#xD;
&#xD;
        -  Others&#xD;
&#xD;
      The secondary objectives of this study are to evaluate efficacy. Further, additional safety&#xD;
      of Remsima™ in RA patients, in comparison with patients receiving non-biologic treatments or&#xD;
      other anti-TNF drugs. Health-economics parameters will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Detection of events of special interest in RA patients</measure>
    <time_frame>every visit, up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score 28 (DAS28)</measure>
    <time_frame>every 6 months, up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>every 6 months, up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Remsima™</arm_group_label>
    <description>Patients who are taking Remsima™ for the treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other anti-TNF drugs</arm_group_label>
    <description>Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biologic naive patients</arm_group_label>
    <description>Biologic naive patients (in Korea only)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for immunogenicity should be retained at the central laboratory up to the End&#xD;
      of the Study, in case additional analysis is required. If additional analysis is not required&#xD;
      during the study or after the End of the Study, blood samples will be stored in a CELLTRION,&#xD;
      Inc. or designated biobank for a further 5 years (from the date the sample is transferred to&#xD;
      the CELLTRION, Inc. or biobank) unless a specific authorization is given by CELLTRION, Inc.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of at least 950 male and female patients with Rheumatoid&#xD;
        Arthritis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients&#xD;
&#xD;
          2. Patients with active RA&#xD;
&#xD;
          3. Patients (or legal guardian, if applicable) who are willing to give informed consent&#xD;
             for long term follow-up including access to all medical records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of hypersensitivity to infliximab&#xD;
&#xD;
          2. Patients with a current or past history of chronic infection&#xD;
&#xD;
          3. Patients with moderate or severe heart failure (NYHA class III/IV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klara Sirova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Revmatologie MUDr. Klara Sirova s.r.o. Chelčického 616/12 , 702 00, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HyeYoung Park</last_name>
    <phone>+82-32-850-6562</phone>
    <email>HyeYoung.Park2@celltrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JooHee Lee</last_name>
    <phone>+82-32-850-6565</phone>
    <email>JooHee.Lee@celltrion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SungHawn Park</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 6, 2021</submitted>
    <returned>October 1, 2021</returned>
    <submitted>October 18, 2021</submitted>
    <returned>November 15, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

